Another mRNA-based vaccine candidate protects animals against SARS-CoV-2

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and non-human primates, researchers report on July 23rd in the journal Cell. Two injections of the vaccine were sufficient to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. “The robust protection observed in the…

Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma after FDA approval

Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be…